SIREN : 407930908
PHARMONWEB is a French company founded 29 years ago, specialized in the sector Régie publicitaire de médias. Based in BEZANNES (51430), this company of category PME shows in 2021 a revenue of 10.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2021 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | 10 452 266 € | N/C | N/C | N/C | 4 870 130 € |
| Net income | 88 010 € | -124 807 € | 42 319 € | 12 194 € | 19 661 € | -10 795 € | 38 211 € |
| EBITDA | N/C | N/C | 87 720 € | N/C | N/C | N/C | 66 120 € |
| Net margin | N/C | N/C | 0.4% | N/C | N/C | N/C | 0.8% |
In 2024, PHARMONWEB generates positive net income of 88 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 38 k€ -> 88 k€.
88 010 €
The debt ratio (= Financial debt / Equity x 100) stands at 457%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 2%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
457.424%
2.364%
32.2%
In 2024, the debt ratio of PHARMONWEB (457.42) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of PHARMONWEB (2.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2021, the repayment capacity of PHARMONWEB (3.18) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 108.42. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
108.421
In 2024, the liquidity ratio of PHARMONWEB (108.42) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2021, the interest coverage of PHARMONWEB (18.2x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Indicative estimate only : the number of comparable transactions in this sector is limited (28 transactions). This range of 94 646€ to 336 148€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 28 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMONWEB with other companies in the same sector:
Voir toutes les statistiques du secteur Régie publicitaire de médias
The revenue of PHARMONWEB in 2021 is 10.5 M€.
Yes, PHARMONWEB generated a net profit of 88 k€ in 2024.
The headquarters of PHARMONWEB is located in BEZANNES (51430), in the department Marne.
The tax return of PHARMONWEB is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMONWEB operates in the sector Régie publicitaire de médias (NAF code 73.12Z). See the 'Sector positioning' section above to compare the company with its competitors.